SUBSCRIBE
SUBSCRIBE

Phase I

Fatty liver, liver steatosis
Drug Development
As Others Falter, Sagimet CEO Confident for Success of Experimental NASH Treatment
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
October 21, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: October 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
October 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Intellia Aims Big with CRISPR Therapy to Cure ATTR
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
October 19, 2020
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Clinical Catch-Up: October 12-16
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
October 16, 2020
 · 
8 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: October 13
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
October 13, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: October 5-9
It was a moderately busy week for clinical trial news. Here’s a look.
October 9, 2020
 · 
9 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: October 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
October 6, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: September 28-October 2
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
October 2, 2020
 · 
9 min read
 · 
Mark Terry
Drug Development
FDA Grants Fast Track Designation to Pfizer’s DMD Gene Therapy
PF-06939926 is currently being evaluated to determine the safety and efficacy of this gene therapy in boys with DMD.
October 1, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial
The trial was initially placed on hold in November 2019 due to safety concerns.
October 1, 2020
 · 
2 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients
May 17, 2024
 · 
2 min read
Drug Development
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
May 16, 2024
 · 
3 min read
Drug Development
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
May 16, 2024
 · 
10 min read
Drug Development
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
May 16, 2024
 · 
6 min read
Business
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
 · 
9 min read
Drug Development
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
 · 
9 min read
Drug Development
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 16, 2024
 · 
8 min read
Drug Development
Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers
May 16, 2024
 · 
4 min read
Drug Development
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
May 16, 2024
 · 
6 min read
Drug Development
South Rampart Pharma Publishes SRP-001’s Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports
May 16, 2024
 · 
6 min read
Drug Development
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024
 · 
20 min read
Drug Development
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
May 16, 2024
 · 
4 min read
Drug Development
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
May 15, 2024
 · 
5 min read
Drug Development
INIMMUNE ANNOUNCES SUCCESSFUL PHASE 1 CLINICAL RESULTS FOR DISEASE MODIFYING ALLERGY TREATMENT, INI-2004
May 15, 2024
 · 
3 min read
Drug Development
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
May 15, 2024
 · 
5 min read
Drug Development
PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
 · 
7 min read
Drug Development
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
May 15, 2024
 · 
9 min read
Drug Development
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024
 · 
5 min read
Drug Development
Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma
May 14, 2024
 · 
3 min read
Drug Development
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) AML Patients at the EHA 2024 Congress
May 14, 2024
 · 
7 min read
Load More